Carcinoid tumours are a type of neuroendocrine neoplasm that typically develop in the neuroendocrine cells of the gastrointestinal (GI) tract, particularly the small intestine, appendix, and rectum. These tumours are distinguished by their slow growth rate and the release of certain hormones and chemicals known as serotonin and other bioactive substances.
Understanding Neuroendocrine Neoplasms
Neuroendocrine cells are specialised cells that produce numerous hormones that control various physiological functions, including metabolism, reproductive health, and stress response. These neuroendocrine cells are the source of neuroendocrine tumours, such as carcinoid tumours.
Classification and Types of Neuroendocrine Neoplasms
Neuroendocrine neoplasms are classified based on location, histological features, and biological behaviour.
Carcinoid tumours
Pancreatic neuroendocrine tumours
Lung carcinoids
Medullary thyroid carcinomas
Merkel cell carcinoma
Causes of Carcinoid Tumours
The exact causes of mutations that lead to carcinoid tumour development are not fully understood, but studies suggest that a combination of the following factors lead to Carcinoid tumours:
Genetic mutations: Change in the DNA of the genes is one of the common causes of rare tumours.
Medical conditions: People with poor stomach and digestive system functioning are more prone to develop this type of cancer.
The exact cause of the growth of the cancerous cells is unknown. Still, the following conditions act as triggers to form tumours-
Type 1 multiple endocrine neoplasia
Type 2 multiple endocrine neoplasia
Syndrome of Von Hippel-Lindau
Neurofibromatosis Type 1
Tuberous Sclerosis Complex
Hormonal Factors: Carcinoid tumours are neuroendocrine tumours, meaning they arise from cells that produce hormones. Imbalances in hormone production and signalling pathways may contribute to tumour development.
Exposure to Certain Chemicals: While not definitively proven, exposure to certain chemicals or environmental factors may sometimes play a role in the development of carcinoid tumours. However, this is not a well-established cause.
Common Signs and Symptoms of Carcinoid Tumours
The clinical presentation of carcinoid tumours can vary widely, depending on the tumour’s location, size, and hormone secretion.
Symptoms of carcinoid tumours in the lungs
Abdominal pain
Skin flushing (face & neck)
Diarrhoea
Wheezing
Weight gain, particularly around the midsection and upper back
Symptoms of carcinoid tumours in the Digestive tract
Abdominal pain
Diarrhoea
Nausea and Vomiting
Rectal bleeding
Rectal pain
Skin flushing
Diagnostic Tests and Imaging Techniques for Detecting Carcinoid Tumours
Accurate diagnosis of carcinoid tumours requires a multidisciplinary approach involving clinical evaluation, laboratory tests, and various imaging modalities.
Blood tests to measure specific markers, such as chromogranin A and serotonin, can aid in the diagnosis.
Urine tests check the excess levels of urine chemicals formed by the breakdown of hormones released by the carcinoid tumours.
Imaging techniques such as Computed tomography (CT) scans, magnetic resonance imaging (MRI), and Somatostatin receptor scintigraphy (SRS) can help localise and characterise the tumours.
Biopsy for tissue observation.
Endoscopy involves passing a scope down the throat to see the inside of the digestive tract.
Bronchoscopy in case of lung carcinoids.
Colonoscopy to diagnose rectal carcinoid tumours.
Metastatic Potential and Patterns of Spread in Carcinoid Tumours
Carcinoid tumours have the potential to metastasise, particularly to the liver. Nevertheless, carcinoid tumours can metastasise to distant sites, such as the lungs, bones, and lymph nodes.
Treatment Approaches
Surgical treatment removes the tumour while preserving organ function completely. Depending on the tumour’s size, location, and extent, various surgical techniques, such as local excision, segmental resection, or radical surgery, may be employed.
Medical therapies to control excess hormones released by the tumour cells.
-Somatostatin analogues, such as octreotide and lanreotide, are commonly prescribed to control hormone secretion, alleviate symptoms, and slow tumour growth.
-Targeted therapies, such as tyrosine kinase inhibitors and mTOR inhibitors, have shown promising results in certain cases, providing more treatment options for patients.
Chemotherapy uses potent drugs to kill tumour cells. This is recommended to treat advanced carcinoid tumours that cannot be removed with surgery.
Targeted drug therapy can cause tumour cells to die by ceasing the activities caused by the growth of the cells. Targeted drug therapy is usually combined with chemotherapy for advanced carcinoid tumours.
Radiation therapy, including external beam radiation and peptide receptor radionuclide therapy (PRRT), has evolved as an effective treatment modality for carcinoid tumours. These techniques aim to destroy tumour cells by delivering high-energy radiation precisely to the target area.
Prognosis
The prognosis of patients with carcinoid tumours varies depending on several factors, including the stage of the disease, tumour grade, primary site, and presence of metastasis. Generally, patients with localised, well-differentiated carcinoid tumours have a more favourable prognosis than those with advanced disease or poorly differentiated tumours.
Lifestyle Modifications and Dietary Considerations for Managing Carcinoid Tumours: Certain lifestyle modifications and dietary adjustments can contribute to the overall management of carcinoid tumours. These may include avoiding potential triggers of symptoms, such as certain foods or stressors, and adopting a balanced diet rich in nutrients. Consulting with a healthcare professional or nutritionist can provide tailored guidance based on individual needs.
Conclusion
Carcinoid tumours are unique neuroendocrine neoplasms that can arise in various locations within the body, more common in the digestive tract and lungs. Understanding the complexities of carcinoid tumours is essential for accurate diagnosis, appropriate treatment decisions, and effective management. Treatment may involve a combination of strategies, including surgery, chemotherapy, and radiation. Advancements in research and therapeutic approaches offer hope for improved outcomes and better quality of life for patients.
FAQs
Q. What are the early warning signs of carcinoid tumours?
A. Early warning signs of carcinoid tumours can vary depending on the location and hormone secretion of the tumour. Common symptoms may include abdominal pain, flushing, diarrhoea, wheezing, and changes in bowel habits.
Q. What are the risk factors for Neuroendocrine tumours?
A. Age, gender, underlying health issues, and family history of the disease are some common risk factors.
Q. What are the symptoms of carcinoid tumours?
A. Symptoms vary depending on the tumour’s location and whether it releases hormones. Common symptoms include flushing, diarrhoea, abdominal pain, wheezing, skin rashes, and heart valve damage.
Q. How are carcinoid tumours treated?
A. Treatment options depend on tumour size, location, and spread. Approaches may include surgery to remove the tumour, medications to control symptoms or slow tumour growth, and, in advanced cases, chemotherapy, radiation therapy, or targeted therapies. Treatment aims to manage symptoms, control tumour growth, and improve quality of life.
No comments:
Post a Comment